Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues-Reference-Cited by-同舟云学术

Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

Published:2012-12-28 Issue:12 Volume:7 Page:e50494
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Pfister Thomas D.,Hollingshead Melinda,Kinders Robert J.,Zhang Yiping,Evrard Yvonne A.,Ji Jiuping,Khin Sonny A.,Borgel Suzanne,Stotler Howard,Carter John,Divelbiss Raymond,Kummar Shivaani,Pommier Yves,Parchment Ralph E.,Tomaszewski Joseph E.,Doroshow James H.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference49 articles.

1. Preclinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers;N Nechiporchik;Eur J Cancer Supplements,2010

2. DNA topoisomerase I inhibitors: Chemistry, biology, and interfacial inhibition;Y Pommier;Chem Rev,2009

3. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas;S Kummar;Cancer Res,2011

4. Makeyev Y, Muggia FM, Rajan A, Giaccone G, Furuta T, et al.. (2012) Topoisomerase I inhibitors: current use and prospects. In: Pommier Y, editor. DNA Topoisomerases and Cancer. New York: Springer. 245–277.

5. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies;BA Teicher;Biochem Pharmacol,2008

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates;Pharmaceutics;2022-08-16

2. Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors;European Journal of Medicinal Chemistry;2022-01

3. What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?;Journal of Oncology Practice;2018-11

4. Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors;Molecular Cancer Therapeutics;2018-02-14

5. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment;Oncotarget;2016-11-24